The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Avatrombopag, rilzabrutinib and COVID-19 updates in ITP
Barbara Skopec, MD, PhD, University Medical Centre Ljubljana, Ljublyjana, Slovenia, shares which abstracts she is most looking forward to at the virtual European Hematology Association (EHA) Congress 2021, in particular highlighting novel data on avatrombopag and rilzabrutinib for patients with immune thrombocytopenia (ITP) and the management of COVID-19 in patients with ITP.
Disclosures
Barbara Skopec, MD, PhD, has received consultancy fees from Amgen and Novartis.
